In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity

In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity,... Int Urol Nephrol (2017) 49:1691–1697 DOI 10.1007/s11255-017-1615-x NEPHROLOGY – ORIGINAL PAPER In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity 1 1 1 Theodoros Eleftheriadis · Georgios Pissas · Maria Sounidaki · 1 2 1 Georgia Antoniadi · Nikolaos Antoniadis · Vassilios Liakopoulos · Ioannis Stefanidis Received: 12 March 2017 / Accepted: 9 May 2017 / Published online: 15 May 2017 © Springer Science+Business Media Dordrecht 2017 Abstract Results In two-way MLRs, tacrolimus inhibited cell prolif- Purpose Acute cellular rejection is the major cause of eration more than everolimus. In one-way MLRs, tacroli- immune-mediated graft failure early in the course of kid- mus and everolimus decreased alloantibody production to ney transplantation, whereas chronic antibody-mediated the same extent. rejection is a major contributor to graft loss in the late post- Conclusions In human cell cultures, everolimus is infe- transplant phase. Based mainly on the results of short-term rior to tacrolimus in inhibiting cellular alloimmunity, but studies, the calcineurin inhibitor tacrolimus prevails over equally effective as regards humoral alloimmunity. Thus, the mammalian target of rapamycin (mTOR) inhibitors. everolimus might be a safe alternative in case of tacroli- However, the toxicity http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Urology and Nephrology Springer Journals

In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity

Loading next page...
 
/lp/springer_journal/in-human-cell-cultures-everolimus-is-inferior-to-tacrolimus-in-HUY50MLcfY
Publisher
Springer Netherlands
Copyright
Copyright © 2017 by Springer Science+Business Media Dordrecht
Subject
Medicine & Public Health; Nephrology; Urology
ISSN
0301-1623
eISSN
1573-2584
D.O.I.
10.1007/s11255-017-1615-x
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial